Program

FRIDAY, 6 September – Pre-conference Education Course

9:00 AM Walk in coffee

9:30 AM Parallel sessions - Integrated training on:
  • Basic colonoscopy  
    Manar Salah, Ain Shams University, Egypt
  • Basic upper endoscopy  
    Ahmed Talaat Elganzory, Ain Shams University, Egypt
  • Point of care testing  
    Elena Ivanova Reipold, FIND, Switzerland; 
    Cynthia Tamandjou, University of Cape Town, South Africa; 
    Shivraj Bhoite, Molbio Diagnostics, India; 
    Marc Amphlett, Genedrive, United Kingdom

11:30 AM Program break - Friday afternoon prayer

1:00 PM Lunch

2:00 PM Opening of the conference  
  Chairs: Manal El-Sayed, MD, PhD

2:15 PM Keynote lecture: Global efforts on viral hepatitis elimination  
  John Ward, MD  
  Centers for Disease Control, USA

2:45 PM What’s new in viral hepatitis - including EASL coverage  
  Thomas Berg, MD  
  University Hospital Leipzig, Germany

3:15 PM Viral hepatitis and pregnancy  
  Wendy Spearman, MD, PhD  
  University of Cape Town, South Africa

3:45 PM Discussion

4:00 PM Break

Session 1 HCC and its management  
  Chairs: Olufunmilayo Lesi, FWACP, FMCP

4:30 PM Epidemiology, burden of disease and outcomes of HCC in Africa  
  Edith Okeke, MD  
  University of Jos, Nigeria

4:55 PM Improving risk stratification and early detection of HCC in Africa  
  Ashraf Omar, MD  
  Cairo University, Egypt

5:20 PM Surgical therapy for HCC – including resection and liver transplantation  
  Mahmoud El-Meteini, MD, M.B.B.CH  
  Ain Shams University, Egypt
5:45 PM  Loco-regional therapy for HCC – including ablation, chemoembolization and hepatic artery embolization  
Benjamin Sarkodie, MD  
University of Ghana School of Medicine & Dentistry, Ghana

6:10 PM  Systemic therapy – what is realistic in the LMIC setting?  
Mitesh Borad, MD  
Mayo Clinic Arizona, USA

6:35 PM  Needs for research and advocacy for HCC in Africa  
Olufunmilayo Lesi, FWACP, FMCP  
WHO Regional Office for Africa, Congo

Discussion

7:00 PM  Welcome reception

SATURDAY, 7 September

8:00 AM  Industry Supported Symposium I - Gilead: SOF/VEL/VOX. Current position in HCV management in today's guidelines

Session 2  Management of viral hepatitis (I) - HBV related  
Chairs: Wendy Spearman MD, PhD & Thomas Berg, MD

9:00 AM  Simplification of HBV treatment algorithm  
Ayman Yosry, MD  
Cairo University, Egypt

9:25 AM  Treatment of HBV in sub-Saharan Africa  
Hailemichael Desalegn, MD  
St. Paul’s Hospital Millennium Medical College, Ethiopia

Abstract-driven presentations:

9:50 AM  Prevalence of Hepatitis B Surface Antigen (HBsAg) positivity and its associated factors in Rwanda/risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program  
Jean Damascene Makuza  
#01-A /#01-B

10:00 AM  Prenatal consultation as a starting point for family screening of hepatitis B virus, the CI cohort ANRS 12359  
Nanelin Alice Guingane  
#02

10:10 AM  Analysis of the National Hepatitis B Viral Load Testing Programme in Uganda  
Viola Kasone  
#03

10:20 AM  High rates of HBV functional cure among HIV/HBV-coinfected patients on ART in Zambia  
Michael Vinikoor  
#04

10:30 AM  Break
Session 3  Management of viral hepatitis (II) - HCV related

Chairs: Mark Nelson, MD, FRCP & Mary Afihene MBChB, FWACP

11:00 AM  Treatment of hepatitis C in SSA (Rwanda)
Neil Gupta, MD
Harvard Medical School, USA

11:25 AM  Hepatitis delta
Mario Rizetto, MD
University of Torino, Italy

Abstract-driven presentations:

11:50 AM  Hepatitis C treatment among people who inject drugs in Kenya: preliminary findings of the test and link to care for injecting drug users study C infection in Rwanda: results from a nationwide screening program
Mercy Nyakowa #05

12:00 PM  Efficacy of Direct-Acting Antiviral (DAA) regimens in HIV/HCV-co-infected patients in Libya
Nagat Bousifi #06

12:10 PM  Assessment of liver fibrosis after Direct-Acting Antiviral therapy in compensated and decompensated HCV-related liver diseases
Mohammed Mohammed #07

12:20 PM  Heading toward hepatitis C virus elimination: Tunisian experience, achievements and prospects
Mouna Safer #08

12:30 PM  Lunch

1:15 PM  Get your paper published in The Lancet
Robert Brierley
The Lancet Gastroenterology & Hepatology, United Kingdom

1:45 PM  HBV Cure Science 101 - organized by ICE-HBV
Anna Kramvis, BScHons, PhD
International Coalition to Eliminate HBV (ICE-HBV) / University of the Witwatersrand, South Africa

Session 4  Public health - Egypt’s model of care

Chairs: Gamal Esmat, MD & John Ward, MD

2:45 PM  Screening of 50 million people
Manal El-Sayed, MD, PhD
Ain Shams University, Egypt

3:05 PM  Scaling up treatment
Wahid Doss, MD
Cairo University, Egypt
3:25 PM  **Round Table discussion: Translation of Egypt’s experience to the rest of Africa**

- Wahid Doss, MD - Cairo University, Egypt
- Gamal Esmat, MD - Cairo University, Egypt
- Magdy El-Serafy, MD - Cairo University, Egypt
- Imam Waked, MB, BCh, MSc, MD, FAASLD - National Liver Institute, Egypt
- Mohamed Hassany, MD - National Hepatology and Tropical Medicine Research Institute, Egypt
- Jean Damascene Makuza, MD - Rwanda Biomedical Center, Rwanda

4:10 PM  Break

**Session 5**  Civil society contribution in Africa - organized by World Hepatitis Alliance  
*Chairs: Cary James & Gamal Shiha, MD, MBBH, MSc*

4:40 PM  **Round table Discussion: the role of patient support groups**

- Cary James - World Hepatitis Alliance, United Kingdom
- Bisi Bright - LiveWell Initiative LWI, Nigeria
- Mohamed El-Wahsh - Tanya Masr, Egypt
- Ammal Metwally, MD, PhD - National Research Center, Egypt
- Coulibaly Alioune Badara, MD - Association pour la Promotion de la Sante et le Developpement (APSAD), Mali
- Kenneth Kabagambe, BA - The National Organisation for People Living with Hepatitis B (NOPLHB), Uganda
- Elodie Sanasee - Prévention Information et Lutte contre le SIDA (PILS), Mauritius

**SUNDAY, 8 September**

8:00 AM  **Industry Supported Symposium II: Economic impact and funding for hepatitis elimination - drawing from Egypt’s success**

**Session 6**  NASH/NAFLD management in Africa  
*Chairs: John Rwegasha MBChB, M.MED, FRCP, MSc & Imam Waked, MB, BCh, MSc, MD, FAASLD*

9:00 AM  **New therapies for NASH/NAFLD**

- Thomas Berg, MD  
  University Hospital Leipzig, Germany

9:30 AM  **Clinical case presentation**

- Imam Waked, MB, BCh, MSc, MD, FAASLD  
  National Liver Institute, Egypt

**Abstract - driven presentations:**

10:00 AM  **HCC developed following DAAs treatment does not display more aggressive pattern**  
Gamal Shiha  #09

10:10 AM  **Factors associated with liver toxicity among HIV infected children and adolescents attending a national referral pediatric HIV clinic in Uganda**  
Bonny Mulindwa  #10

10:20 AM  **Prevalence of fatty liver disease and associated factors among outpatients attending internal medicine clinics at Muhimbili University of Health and Allied Sciences Academic Medical Centre, Tanzania**  
Nontobeko Simelane  #11

10:30 AM  **Best of Posters**  
*Chairs: Mark Nelson, MD, FRCP & Manal El-Sayed, MD, PhD*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>Break</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Industry Supported Symposium III - Pharco: Innovation of access to treatment: Real Life Scenarios</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

**Session 7  WHO sponsored session on viral hepatitis and universal health coverage**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 PM</td>
<td>The global and regional hepatitis elimination agenda</td>
</tr>
<tr>
<td></td>
<td><strong>Joumana Hermez</strong></td>
</tr>
<tr>
<td></td>
<td>WHO/EMRO, Egypt</td>
</tr>
<tr>
<td>2:10 PM</td>
<td>Access to hepatitis B and C medicines</td>
</tr>
<tr>
<td></td>
<td><strong>Morgane Ahmar</strong></td>
</tr>
<tr>
<td></td>
<td>International Treatment Preparedness Coalition (ITPC), Morocco</td>
</tr>
<tr>
<td>2:20 PM</td>
<td>Leaving no one behind: role of civil society in reaching people who inject drugs (PWID) for hepatitis elimination</td>
</tr>
<tr>
<td></td>
<td><strong>Elie Aaraj</strong></td>
</tr>
<tr>
<td></td>
<td>Middle East and North Africa Harm Reduction Association (MENAHRA), Lebanon</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Innovative financing and financial protection: inclusion of viral hepatitis services</td>
</tr>
<tr>
<td></td>
<td><strong>Awad Mataria, PhD</strong></td>
</tr>
<tr>
<td></td>
<td>WHO/EMRO, Egypt</td>
</tr>
<tr>
<td>2:40 PM</td>
<td>Fitting viral hepatitis elimination in the UHC agenda</td>
</tr>
<tr>
<td></td>
<td><strong>Awad Mataria, PhD</strong></td>
</tr>
<tr>
<td></td>
<td>WHO/EMRO, Egypt</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

**Closure of the conference**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>Conference Summary and Conclusions from the Conference Co-Chairs</td>
</tr>
<tr>
<td></td>
<td><strong>Manal El-Sayed &amp; Charles Boucher</strong></td>
</tr>
<tr>
<td></td>
<td>Ain Shams University, Egypt &amp; Erasmus Medical Center, the Netherlands</td>
</tr>
<tr>
<td>3:50 PM</td>
<td>President of Ain Shams University speech</td>
</tr>
<tr>
<td></td>
<td><strong>Mahmoud El-Meteini</strong></td>
</tr>
<tr>
<td></td>
<td>Ain Shams University, Egypt</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Minister of Health speech</td>
</tr>
<tr>
<td></td>
<td><strong>Her Excellency Dr. Hala Zayed</strong></td>
</tr>
<tr>
<td></td>
<td>Ministry of Health, Egypt</td>
</tr>
<tr>
<td>4:10 PM</td>
<td>Minister of Investment and International Cooperation speech</td>
</tr>
<tr>
<td></td>
<td><strong>Her Excellency Dr. Sahar Nasr</strong></td>
</tr>
<tr>
<td></td>
<td>Ministry of Investment and International Cooperation, Egypt</td>
</tr>
<tr>
<td>4:20 PM</td>
<td>Minister of Higher Education speech</td>
</tr>
<tr>
<td></td>
<td><strong>His Excellency Prof. Khaled Abdel-Ghaffar</strong></td>
</tr>
<tr>
<td></td>
<td>Ministry of Higher Education, Egypt</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Closure of the conference</td>
</tr>
</tbody>
</table>